

**Anti-Pancreatic Polypeptide (human, PP)  
Mouse monoclonal antibody**

Subclass: IgG1/k  
Clone: 6

CAT. NO. **ABS 030-06**

SPECIFICITY	ABS 030-06 binds human full length pancreatic polypeptide. Cross-reactivity with NPY and PYY was <0.1%.
IMMUNOGEN	Synthetic human PP
TESTED APPLICATIONS	ELISA, WB
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPI TOPE SPECIFICITY	Not determined

**PRESENTATION**

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

**APPLICATION**

**ELISA:** ABS 030-06 binds free PP in solution.  
ABS 030-06 reacts in ELISA with PP coated directly onto the microtiter well.  
**WB:** ABS 030-06 can be used in Western blotting.

**TARGET**

Pancreatic polypeptide (PP) is a 36 amino acid residue peptide with sequence and 3-D structural homology with NPY and PYY. PP is the least conserved of the three peptides and was the first to be identified. It is almost exclusively expressed in the endocrine pancreas and released in response to cholinergic stimulation and food intake. PP has inhibitory effects on gall bladder secretion, intestinal motility and pancreatic secretion. PP may serve as a marker for certain gut endocrine tumors including carcinoid tumors.

**REFERENCES**

**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.